Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

PRTO vs AKTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AKTX Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 7–1 Matrix Metrics)

AKTX Overall Winner 6-Pillar Tally: PRTO 1 – 2 AKTX (3 Tie) Matrix Metrics: PRTO 1 – 7 AKTX

As of Nov 20, 2026, Akari Therapeutics plc (AKTX) is the stronger overall head-to-head candidate over PRTO (PRTO) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). PRTO carries a Unified Composite Score of 33.3/100 (SELL) at $24.45 (N/M Forward P/E, N/A operating margin), whereas AKTX carries 50.1/100 (HOLD) at $7.18 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: PRTO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.6); meanwhile AKTX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PRTO vs AKTX
PRTO US Equity
PRTO
Institutional Equity
$24.45
-3.36% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.89β · 21% Vol
Unified Composite Score
33.3 / 100 SELL
Tech 12.0 Fund 36.0 Flow 50.0 Mom 34.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.3%), weak momentum, RSI 23
RSI-14: 22.6 · SMA20: $26.61 · SMA50: $27.03
AKTX NASDAQ Head-to-Head Winner
Akari Therapeutics plc ADR (0.01 USD)
Pharmaceutical Preparations
$7.18
+7.0% 1D
Market Cap $15.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 77.35β · 143% Vol
Unified Composite Score
50.1 / 100 HOLD
Tech 65.0 Fund 56.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.3 · SMA20: $7.52 · SMA50: $8.48

6-Pillar Scorecard Institutional Category Breakdown (PRTO 1 – 2 AKTX)

Columns: Metric · PRTO · AKTX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale AKTX
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A N/A
Market Cap N/A $15.6M
3. Profitability & Quality AKTX
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -146.3%
4. Balance Sheet & Cash Flow PRTO
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $7.66 Book/Sh · -146.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PRTO (1) vs AKTX (7)
Institutional Metric PRTO AKTX Criterion Row Edge
Market Capitalization
Scale
N/A $15.6M Larger Scale AKTX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth AKTX
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin AKTX
Net Profit Margin
Profitability
N/A 0.0% Higher Margin AKTX
Return on Equity (ROE)
Capital Efficiency
N/A -146.3% Higher ROE AKTX
52-Week Range Position
Momentum
0% ($24–$29) 24% ($0–$29) Stronger Trend AKTX
Beta / 30D Volatility
Risk Regime
0.89β · 21% Vol 77.35β · 143% Vol Lower Realized Risk PRTO
Unified Institutional Score
Composite Signal
33.3 / 100 (SELL) 50.1 / 100 (HOLD) Higher Composite AKTX
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A ($7.66 Book/Sh · -146.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PRTO +1.8 pp
PRTO: -9.56% · AKTX: -11.36%
3M Horizon AKTX +5.77 pp
PRTO: -14.31% · AKTX: -8.54%
6M Horizon AKTX +51.1 pp
PRTO: -11.41% · AKTX: +39.69%
1Y Horizon AKTX +5159.61 pp
PRTO: -3.39% · AKTX: +5156.22%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PRTO vs AKTX. Trailing 12-month operating profitability (PRTO N/A vs AKTX 0.0%) and valuation multiples (PRTO N/M vs AKTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PRTO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
AKTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-146.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PRTO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PRTO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AKTX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AKTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PRTO Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AKTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PRTO vs AKTX Key Questions & Quantitative Answers

As of Nov 20, 2026, Akari Therapeutics plc (AKTX) is the stronger overall head-to-head candidate over PRTO (PRTO) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). PRTO carries a Unified Composite Score of 33.3/100 (SELL) at $24.45 (N/M Forward P/E, N/A operating margin), whereas AKTX carries 50.1/100 (HOLD) at $7.18 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: PRTO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.6); meanwhile AKTX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AKTX leads the Growth & Scale pillar: PRTO posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with AKTX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PRTO generates N/A in USD-normalized revenue versus N/A for AKTX. In operating R&D and SG&A reinvestment, PRTO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AKTX.

PRTO and AKTX trade at balanced relative valuation multiples. PRTO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas AKTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PRTO (N/A ROE) versus AKTX (-146.3% ROE) capital efficiency.

In options market volatility and institutional positioning, PRTO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.89β · 21% Vol realized risk). By comparison, AKTX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (77.35β · 143% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.